TITLE

2012 - Review: Omega-3 fatty acid supplements provide no protective benefit in cardiovascular disease

AUTHOR(S)
Halim, Sharif A.; Newby, L. Kristin
PUB. DATE
August 2012
SOURCE
ACP Journal Club;8/21/2012, Vol. 157 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Question: In patients with cardiovascular (CV) disease, are omega-3 fatty acid supplements (eicosapentaenoic acid [EPA] and docosahexaenoic acids [DHA]) effective for secondary prevention? Review scope: Included studies compared omega-3 fatty acid supplements used for >= 1 year with placebo in adults >= 18 years of age who had a history of CV disease, and reported such outcome measures as CV events, sudden cardiac death, CV death, all-cause mortality, myocardial infarction, congestive heart failure, and transient ischemic attack (TIA) or stroke. Review methods: PubMed, EMBASE/Excerpta Medica, and Cochrane Library (all to Apr 2011), and bibliographies were searched for English-language, double-blind, placebo-controlled, randomized trials. 14 trials (n = 20 485, mean age 63 y, 79% men) met the selection criteria. Mean follow-up was 2 years, and mean daily dose of EPA or DHA was 1.7 g/d. 6 trials had Jadad scores of 5 out of 5, 7 had scores of 4, and 1 had a score of 3. Main results: Meta-analysis showed that omega-3 fatty acids reduced CV mortality compared with placebo (Table). Groups did not differ for CV events, sudden cardiac mortality, all-cause mortality, myocardial infarction, congestive heart failure, or TIA or stroke (Table). Conclusion: In patients with cardiovascular disease, omega-3 fatty acid supplements do not reduce adverse cardiovascular outcomes.
ACCESSION #
79360801

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics